Stocks and InvestingStocks and Investing
Mon, April 4, 2022
Sun, April 3, 2022
Fri, April 1, 2022
Thu, March 31, 2022
Wed, March 30, 2022
Tue, March 29, 2022

Judah Frommer Maintained (ABOS) at Buy with Decreased Target to $17 on, Mar 29th, 2022


Published on 2024-10-27 20:13:08 - WOPRAI, Judah Frommer
  Print publication without navigation


Judah Frommer of Credit Suisse, Maintained "Acumen Pharmaceuticals, Inc." (ABOS) at Buy with Decreased Target from $26 to $17 on, Mar 29th, 2022.

Judah has made no other calls on ABOS in the last 4 months.



There is 1 other peer that has a rating on ABOS. Out of the 1 peers that are also analyzing ABOS, 0 agree with Judah's Rating of Hold.



This is the rating of the analyst that currently disagrees with Judah


  • Geoff Meacham of "B of A Securities" Upgraded from Hold to Strong Buy and Decreased Target to $14 on, Friday, January 21st, 2022